INSIGHTS
-
FDA Approves a New Sunscreen Ingredient for the First Time in 20 Years: What It Means for You
For the first time in two decades, Americans are finally getting access to a new sunscreen active ingredient. On June 9, 2026, the U.S. Food and Drug Administration (FDA) officially approved bemotrizinol as a permitted sunscreen filter, marking a major shift in how well U.S. sunscreens can protect against the sun’s most harmful rays. If…
-
FDA Accepts First In Silico Drug Development Tool Under ISTAND Program to Help Predict Drug‑Induced Liver Injury
The U.S. Food and Drug Administration has taken an important step toward modernizing how new medicines are evaluated before they ever reach human testing. In early June 2026, the agency announced that it accepted the first Letter of Intent for an in silico, or computer‑based, drug development tool designed to help predict drug‑induced liver injury.…
-
AD109 and the SynAIRgy Phase 3 Trial: What a Once Daily Pill Could Mean for Treating Obstructive Sleep Apnea
Obstructive sleep apnea, or OSA, affects millions of adults and often goes untreated because the most common therapy – the CPAP machine – can be uncomfortable or difficult to use every night. Many people simply cannot tolerate the mask, the noise, or the feeling of forced air. For years, researchers have been searching for an…
-
FDA Approves Cavhanza for Philadelphia Chromosome Positive Chronic Myeloid Leukemia
When the FDA approves a new cancer treatment, it often signals a meaningful step forward for patients who need more flexible or effective options. That is exactly what happened with Cavhanza, a newly approved orally disintegrating tablet (ODT) formulation of nilotinib for adults with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML). Cavhanza is designed…
-
FDA Approves Decnupaz, the First Antibody-Drug Conjugate for Blastic Plasmacytoid Dendritic Cell Neoplasm
The U.S. Food and Drug Administration has approved Decnupaz (pivekimab sunirine-pvzy), marking a major step forward for people facing blastic plasmacytoid dendritic cell neoplasm, or BPDCN. This is an extremely rare and aggressive blood cancer that has historically offered patients very few effective treatment options. With this approval, adults diagnosed with BPDCN – whether newly…
-
The American Cancer Society Now Recommends Blood Tests As A New Option For Colorectal Cancer Screening
Colorectal cancer has long been one of the most preventable yet deadly cancers in the United States. For years, doctors have emphasized the importance of screening because catching this cancer early can dramatically improve survival. Now, the American Cancer Society (ACS) has updated its guidelines to include a new tool in the fight against colorectal…
-
Datroway Receives FDA Approval for Advanced Triple‑Negative Breast Cancer: What This Breakthrough Means for Patients
Triple‑negative breast cancer, often shortened to TNBC, has long been one of the most challenging forms of breast cancer to treat. Unlike other breast cancer types, TNBC does not have the three common receptors that many modern treatments target. This means patients have historically had fewer options, and many have had to rely on chemotherapy…
-
FDA Approves Fasenra as an Under the Skin Shot to Help Reduce Flares in Hypereosinophilic Syndrome
When the FDA approves a new treatment for a rare and difficult condition, it often marks a turning point for patients who have spent years dealing with unpredictable symptoms. That is exactly what happened with the approval of Fasenra, a medication given as an under the skin shot that has now been cleared to help…
-
FDA Warns Consumers Not To Use Expired Amazon Basic Care Levonorgestrel 1.5 mg
The FDA has issued a safety alert advising consumers to stop using any expired Amazon Basic Care Levonorgestrel 1.5 mg tablets. This alert matters because levonorgestrel is a form of emergency contraception, and using an expired dose can reduce its effectiveness. When a product meant to prevent pregnancy loses potency, the consequences can be serious…
-
FDA Warns of Increased Risk of New Blood Cancers Linked to Tazverik
Tazverik, a prescription cancer drug used to treat certain rare cancers, has recently come under closer scrutiny by the U.S. Food and Drug Administration. In a safety alert, the FDA warned health care providers and patients about an increased risk of developing new blood cancers in people treated with Tazverik. This announcement has raised understandable…